<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarter ended December 27, 1997.
Commission file number 0-14742
CANDELA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 04-2477008
(State or other jurisdiction No.) (I.R.S. Employer Identification
of incorporation or organization)
530 Boston Post Road, Wayland, Massachusetts 01778
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (508) 358-7400
_______________________
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [_]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date.
Class Outstanding at February 5, 1998
--------------- -------------------------------
Common Stock, $.01 par value 5,435,679
================================================================================
<PAGE>
CANDELA CORPORATION
INDEX
<TABLE>
<CAPTION>
Page(s)
-------
<S> <C>
Part I. Financial Information:
Item 1. Consolidated Balance Sheets 3
Consolidated Statements of Operations 4
Consolidated Statements of Cash Flows 5
Notes to Consolidated Financial
Statements 6-7
Item 2. Management's Discussion and
Analysis of Financial Condition
and Results of Operations 8-14
Part II. Other Information:
Item 6. Exhibits and Reports on Form 8-K 15
Exhibit 27.1 Financial Data Schedule 17
</TABLE>
2
<PAGE>
CANDELA CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
<TABLE>
<CAPTION>
December 27, June 28,
1997 1997
ASSETS (unaudited)
- ----------------------------------------------------------------------------
<S> <C> <C>
Current assets:
Cash and equivalents $ 1,727 $ 2,674
Accounts receivable 5,228 8,848
Notes receivable 1,345 1,284
Inventory 7,550 6,776
Other current assets 486 522
- ----------------------------------------------------------------------------
Total current assets 16,336 20,104
- ----------------------------------------------------------------------------
Property and equipment, net 3,380 3,523
Other assets 863 1,210
- ----------------------------------------------------------------------------
Total Assets $20,579 $24,837
============================================================================
LIABILITIES AND STOCKHOLDERS' EQUITY
- ----------------------------------------------------------------------------
Current liabilities:
Lines of credit and short-term notes $ 2,321 $ 1,488
Current portion of long-term debt 345 339
Deferred income 1,743 2,071
Accounts payable 4,149 5,879
Accrued payroll and related expenses 739 833
Accrued warranty costs 1,239 1,338
Income taxes payable 358 516
Other accrued liabilities 1,154 608
Reserve for restructuring costs 2,609 0
- ----------------------------------------------------------------------------
Total current liabilities 14,657 13,072
- ----------------------------------------------------------------------------
Long-term debt 1,227 1,519
- ----------------------------------------------------------------------------
Stockholders' equity:
Common stock 54 54
Additional paid-in capital 17,300 17,223
Accumulated deficit (12,177) (6,885)
Cumulative translation adjustment (482) (146)
- ----------------------------------------------------------------------------
Total stockholders' equity 4,695 10,246
- ----------------------------------------------------------------------------
Total Liabilities and
Stockholders' Equity $20,579 $24,837
============================================================================
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
3
<PAGE>
CANDELA CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
<TABLE>
<CAPTION>
For the three months ended: For the six months ended:
December 27, December 28, December 27, December 28,
1997 1996 1997 1996
(unaudited) (unaudited)
- --------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Revenue $ 8,522 $ 9,406 $16,345 $17,045
Cost of sales 4,824 4,750 9,326 8,635
- --------------------------------------------------------------------------------------------------------------
Gross profit 3,698 4,656 7,019 8,410
Operating expenses:
Research and development 742 555 1,320 1,127
Selling, general and administrative 4,695 3,031 8,090 5,537
Restructuring costs 2,609 0 2,609 0
- ------------------------------------------------------------------------------------------------------------
Total operating expenses 8,046 3,586 12,019 6,664
- ------------------------------------------------------------------------------------------------------------
(Loss) income from operations (4,348) 1,070 (5,000) 1,746
Other income (expense):
Interest income 9 16 17 31
Interest expense (69) (15) (135) (31)
Other (33) (20) (96) 33
- ------------------------------------------------------------------------------------------------------------
Total other income (expense) (93) (19) (214) 33
- ------------------------------------------------------------------------------------------------------------
(Loss) income before income taxes (4,441) 1,051 5,214 1,779
Provision for income taxes 0 315 78 534
- ------------------------------------------------------------------------------------------------------------
Net (loss) income $(4,441) $ 736 $(5,292) $ 1,245
============================================================================================================
Basic earnings (loss) per share $ (0.82) $ 0.14 $ (0.97) $ 0.23
Diluted earnings (loss) per share $ (0.78) $ 0.13 $ (0.94) $ 0.22
============================================================================================================
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
4
<PAGE>
CANDELA CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
<TABLE>
<CAPTION> For the six months ended:
Dec 27, Dec 28,
1997 1996
(unaudited)
- -------------------------------------------------------------------------------------------------
<S> <C> <C>
Cash flows from operating activities: $ (5,292) $ 1,245
Net income (loss)
Adjustments to reconcile net income (loss) to net
cash provided by (used for) operating activities:
Depreciation and amortization 380 235
Provision for restructuring charges 2,609
Change in assets and liabilities:
Accounts receivable 3,312 (1,687)
Notes receivable (188) 1,121
Inventory (965) 450
Other current assets 18 (360)
Other assets 336 (465)
Accounts payable (1,410) 840
Accrued payroll and related expenses (102) (27)
Deferred income (287) (163)
Accrued warranty costs (88) 174
Income taxes payable (193) 447
Other accrued liabilities 569 (407)
- -------------------------------------------------------------------------------------------------
Total adjustments 3,991 158
- -------------------------------------------------------------------------------------------------
Net cash provided by (used for) operating activities (1,301) 1,403
- -------------------------------------------------------------------------------------------------
Cash flows from investing activities:
Proceeds from sale of equipment 0 45
Payment for additions to property
and equipment (141) (889)
- -------------------------------------------------------------------------------------------------
Net cash used for investing activities (141) (844)
- -------------------------------------------------------------------------------------------------
Cash flows from financing activities:
Payments of capital lease obligations (198) (51)
Issuance (payment) of long-term debt 754 (334)
Proceeds from the issuance of common stock 76 85
- -------------------------------------------------------------------------------------------------
Net cash provided by (used for) financing activities 632 (300)
- -------------------------------------------------------------------------------------------------
Accumulated translation adjustment (137) (152)
- -------------------------------------------------------------------------------------------------
Net increase (decrease) in cash and equivalents (947) 107
- -------------------------------------------------------------------------------------------------
Cash and equivalents at beginning of period 2,674 3,041
- -------------------------------------------------------------------------------------------------
Cash and equivalents at end of period $ 1,727 $ 3,148
=================================================================================================
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
5
<PAGE>
CANDELA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The accompanying financial statements and notes do not include all of the
disclosures made in the Company's Annual Report on Form 10-K for fiscal 1997,
which should be read in conjunction with these statements. The financial
information included herein, with the exception of the consolidated balance
sheet at June 28, 1997 has not been audited. However, in the opinion of
Management, these consolidated financial statements include all necessary
adjustments for a fair presentation of the quarterly results and are prepared
and presented in a manner consistent with the Company's annual report on Form
10-K. The results for the three and six month periods ended December 27,
1997 are not necessarily indicative of the results to be expected for the
full year.
2. INVENTORY
Inventory consists of the following (in thousands):
<TABLE>
<CAPTION>
December 27, 1997 June 28, 1997
------------------ -------------
(unaudited) /(1)/
<S> <C> <C>
Raw materials $3,069 $2,429
Work in process 1,177 1,023
Finished goods 3,304 3,324
------ ------
$7,550 $6,776
====== ======
</TABLE>
3. PROPERTY AND EQUIPMENT
Property and equipment consists of the following (in thousands):
<TABLE>
<CAPTION>
December 27, 1997 June 28, 1997
----------------- -------------
(unaudited) /(1)/
<S> <C> <C>
Leasehold improvements $ 2,092 $ 2,014
Office furniture & equipment 1,070 1,064
Laser systems 483 483
Equipment 4,411 4,271
------- -------
Total 8,056 7,832
Less accumulated depreciation
and amortization (4,676) (4,309)
------- -------
$ 3,380 $ 3,523
======= =======
</TABLE>
/(1)/ Derived from audited financial statements
6
<PAGE>
CANDELA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
4. NET INCOME PER COMMON AND COMMON EQUIVALENT SHARE
Net income per share is computed by dividing net income by the weighted
average number of shares of common stock and, if dilutive, common stock
equivalents outstanding. Common stock equivalents include shares issuable
upon the exercise of stock options or warrants, net of shares assumed to have
been purchased with the proceeds.
<TABLE>
<CAPTION>
For the three months ended For the six months ended
--------------------------- -------------------------
December 27 December 28 December 27 December 28
1997 1996 1997 1996
------------- ------------ ------------ -----------
<S> <C> <C> <C> <C>
NUMERATOR
- ---------
Net income(loss) $ (4,441) $ 736 $ (5,292) $ 1,245
======== ======== ======== ========
DENOMINATOR
- -----------
BASIC EARNINGS PER SHARE
- ------------------------
Weighted average shares
outstanding 5,443 5,394 5,443 5,394
-------- -------- -------- --------
Earnings(loss) per share $ (0.82) $ 0.14 $ (0.97) $ 0.23
======== ======== ======== ========
DILUTED EARNINGS PER SHARE
- -------------------------------
Weighted average shares
outstanding 5,443 5,394 5,443 5,394
Dilutive options 231 264 216 275
-------- -------- -------- --------
Adjusted weighted average
shares outstanding 5,674 5,658 5,659 5,669
-------- -------- -------- --------
Earnings(loss) per share $ (0.78) $ 0.13 $ (0.94) $ 0.22
======== ======== ======== ========
</TABLE>
5. RESTRUCTURING COSTS AND OTHER CHARGES
During the quarter ended December 27, 1997, the Company recorded
restructuring charges of $2,609,000 resulting from management's decision to
close the LaserSpa(TM) located in Scottsdale, Arizona. In addition, the
Company recorded a charge of $550,000 against earnings principally for the
purpose of covering accounts and notes receivable from one of Candela's
distributors of medical devices.
7
<PAGE>
CANDELA CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW:
- ---------
Candela Corporation develops, manufactures, and distributes innovative
clinical solutions that enable physicians, surgeons and personal care
practitioners to treat selected cosmetic and medical problems using lasers,
cryosurgery and other proven technologies. In addition, the Company operates
a Company-owned LaserSpa(TM) (a combination skin care center and spa).
The Company has continued to accumulate losses from its wholly-owned
subsidiary, Candela Skin Care Centers, Inc. ("CSCC"), which in turn has utilized
significant cash reserves, while the laser operation (the manufacture, sale and
servicing of lasers) continued to post positive operating trends. As a result
of the continued losses from CSCC the Company has decided to close the
Scottsdale LaserSpa.(TM) Based on this decision a charge of $2,609,000 was made
against second quarter income to cover the cost of closing the Scottsdale
facility. The Company continues to operate one LaserSpa(TM) located in Boston,
Massachusetts. The following discussion and analysis is based on the increasing
significance of revenue and costs associated with the operation of the skin care
centers in relation to the Company in total, and reflects the impact of the
additional charge on the results of operations stated herein.
RESULTS OF OPERATIONS
- ---------------------
Total revenue for the three and six months ended December 27, 1997 was
$8,522,000 and $16,345,000 respectively. For the three-month period ended
December 27, 1997 revenue decreased 9% versus the same period a year earlier.
For the six-month period ended December 27, 1997 revenue decreased 4% versus the
same period last year. Compared to the same period a year earlier, the decrease
for the three and six month periods reflects a lower level of shipments to a
South Korean distributor and elsewhere in the Far East. Additionally, increased
price pressure has resulted in a lower average selling price than in prior
periods. Revenues for CSCC reflect a 20% increase resulting from a full period
of operation for each spa location during the fiscal year 98 six-month period
compared to partial operations in the same period a year earlier.
<TABLE>
<CAPTION>
($ in 000's)
Revenue for the six-month period
--------------------------------
FY 98 FY 97 Change
-------- -------- -------
<S> <C> <C> <C>
Laser operations $14,986 $15,912 -5.8%
Skin care centers 1,359 1,133 19.9%
------- -------
Total $16,345 $17,045 -4.1%
</TABLE>
Gross margins were 43% for both the three and six month periods ending
December 27, 1997, compared to gross margins of 49% for the three and six month
periods a year earlier. The decline in gross margin reflects lower volume of
higher margin units and the impact of selling price pressures principally in the
Far East.
Research and development spending associated with laser operations increased
to $742,000 and $1,320,000 for the three and six months ended December 27, 1997,
respectively. These amounts reflect increases of 34% and 17% over the same three
and six month periods the year before. Such increases are the result of the
Company's development efforts on a number of new projects that will enhance the
laser product lines.
8
<PAGE>
Selling, general and administrative expenses for the three and six month
periods ending December 27, 1997 were $4,695,000 and $8,090,000, representing
increases of 55% and 46%, respectively, versus the same period a year earlier.
The increases in this area reflect a provision in uncollectible notes and
accounts receivable during the quarter of $678,000, including a charge of
$550,000 for accounts receivable from a distributor, and miscellaneous one-time
charges for legal and consulting of $328,000. Additionally, the Company's
entry into the skin care clinic market has accounted for an increase of $910,000
in expenses over the same period a year earlier.
During the quarter ended December 27, 1997, a restructuring charge was made
against income in the amount of $2,609,000. This charge represents the
anticipated costs associated with closing the Scottsdale, Arizona, LaserSpa(TM),
including costs of maintaining the facility, write-off of leasehold
improvements, and a reserve against a loss upon liquidation of the equipment at
the site.
Loss from operations was $4,348,000 and $5,000,000, respectively, for the
three and six months ended December 27, 1997. For the same periods one year
earlier profit from operations was $1,070,000 and $1,746,000, respectively.
Other income and expense for the three-month and six-month period ended
December 27, 1997, reflected expenses of $93,000 and $214,000, respectively.
The same periods a year earlier reflected expense of $19,000 for the second
quarter and income for the six-month period of $33,000. This increase in
expenses for the current year represents an increase in the level of interest
expense resulting from the increased level of debt combined with losses
resulting from foreign currency transactions.
The provision for income taxes results from a combination of activities of
both the domestic and foreign subsidiaries of the Company. Provision for income
taxes for the six months ended December 27, 1997, reflects the utilization of a
portion of the Company's domestic net operating loss carryforwards and minimum
tax provisions calculated in Japan at a rate in excess of the U.S. statutory tax
rate, yielding an effective tax rate of 30%.
9
<PAGE>
CANDELA CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(CONTINUED)
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
The Company has continued to utilize cash resources in the development of the
LaserSpas.(TM) For the six months ending December 27, 1997, cash used for
operating and investing activities totaled $1,442,000 which was partially offset
by additional borrowing against a bank line of credit in the amount of $754,000.
After giving consideration for payments against lease obligations, net cash
provided by financing activities totaled $632,000.
Cash and equivalents at December 27, 1997 decreased to $1,727,000 from
$2,674,000 at June 28, 1997. Major factors impacting this change include
payments for additions to property and equipment, payment of capital lease
obligations, and the use of cash for operating activities of $1,301,000.
After reassessing the future funding requirements of the Scottsdale, Arizona
LaserSpa(TM), it was decided to close the facility in December 1997. The
Company is attempting to sub-lease the facility and will liquidate any equipment
that remains at the location. Equipment leasing has provided a portion of the
funds used by the Company for the initial capital investment costs for this
facility. The lease covering the equipment will be reduced to the extent that
leased equipment is liquidated from the Scottsdale facility.
CSCC's facility in Boston, Massachusetts, reopened as a LaserSpa(TM) in April
1997. That location, situated in one of Boston's best residential/commercial
areas, with an established clientele, continues to conduct business as usual and
is not expected to require a significant amount of cash resources in the future.
Equipment leasing has provided a portion of the capital required to convert this
facility to a combination skin care center and spa, the remainder of the
required funding has been advanced from the parent company.
In support of the Company's laser production operations and the development
of CSCC's LaserSpa(TM) operations, the Company obtained a renewable $3,500,000
line of credit with a major bank during fiscal 1997. The line of credit bore
interest at 1/2% over the bank's prime lending rate and is secured by total
domestic and international accounts receivable and inventory and a pledge of the
stock of CSCC. At December 27, 1997, the Company had utilized $1,950,000 of the
line of credit at an interest rate of 9%.
The Company was not in compliance with the financial covenants contained in
the line of credit as of December 27, 1997, but such covenants have been waived
by the bank. The line of credit expired by its terms on December 31, 1997, and
is currently under review by the bank for potential renewal.
10
<PAGE>
The Company's Japanese subsidiary has borrowed funds to be used for payment
of equipment purchases made from the parent corporation. At December 27, 1997,
this liability is $562,000, converted at the quarter-end exchange rate. The
Company's remaining short-term and long-term debt is comprised of capital lease
obligations which were $2,666,000 and $1,227,000, respectively, at December 27,
1997, compared to $1,827,000 and $1,519,000, respectively, at June 28, 1997.
The Company continues to pursue lines of credit from alternative sources and
private sector sources of funds. There can be no assurance that such funding
will be available on terms acceptable to the Company, or at all, and if external
sources of financing do not become available, the Company's operations could be
adversely impacted.
11
<PAGE>
CANDELA CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(CONTINUED)
CAUTIONARY STATEMENTS
In addition to the other information in this Quarterly Report on Form 10-Q,
the following cautionary statements should be considered carefully in
evaluating the Company and its business. Statements contained in this
Form 10-Q that are not historical facts (including, without limitation,
statements concerning anticipated operational and capital expense levels and
such expense levels relative to the Company's total revenues) and other
information provided by the Company and its employees from time to time may
contain certain "forward-looking" information, as that term is defined by (i)
the Private Securities Litigation Reform Act of 1995 (the "Act") and, (ii) in
releases made by the Securities and Exchange Commission (the "SEC"). The
factors identified in the cautionary statements below, among other factors,
could cause actual results to differ materially from those suggested in such
forward-looking statements. The cautionary statements below are being made
pursuant to the provisions of the Act and with the intention of obtaining the
benefits of the "safe harbor" provisions of the Act.
VARIABILITY OF QUARTERLY OPERATING RESULTS. The Company's quarterly
operating results may vary significantly from quarter to quarter, depending
upon factors such as the timing of product sales, the timing of expenditures in
anticipation of future product orders, the introduction and market acceptance
of new products, effectiveness in managing manufacturing processes, changes in
cost and availability of labor and product components, order cancellations, the
budgetary cycles of its customers, the timing of regulatory approvals and the
cost of operating the LaserSpa(TM) owned by the Company's wholly-owned
subsidiary, Candela Skin Care Centers, Inc. (CSCC). The Company's ability to
accurately forecast future revenues and income for any period is necessarily
limited, and any forward-looking information provided from time to time by the
Company represents only management's then-best current estimate of future
results or trends, and actual results may differ materially from those
contained in the Company's estimates.
POTENTIAL VOLATILITY OF STOCK PRICE. There has been significant volatility
in the market price of securities of companies in the medical device industry.
Factors such as announcements of new products by the Company or its
competitors, quarterly fluctuations in the financial results of the Company or
its competitors, shortfalls in the Company's actual financial results compared
to results previously forecast by stock market analysts, conditions in the
medical device industry and the financial markets and the economy generally
could cause the market price of the Company's securities to fluctuate
substantially and may adversely affect the price of the Company's securities.
12
<PAGE>
CANDELA CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(CONTINUED)
RISKS ASSOCIATED WITH INTERNATIONAL OPERATIONS. A significant portion of
the Company's revenues are attributable to international operations and
revenues from international operations are likely to continue to represent a
significant portion of the Company's revenues in future periods. The Company's
international business and financial performance may be adversely affected by a
number of factors, including without limitation, fluctuations in exchange
rates, tariffs and other trade barriers, adverse tax regulation, and adverse
political and economic conditions. Adverse effect on the Company's
international operations may have materially adverse effects on the Company's
overall financial condition and operating results.
BUSINESS STRATEGIC DEVELOPMENT. While continuing to expand and diversify
its core cosmetic and surgical laser equipment business, the Company embarked
on a new business strategy of opening combined spa and laser cosmetic skin care
centers. Currently the Company operates a combined spa/skin care facility in
Boston, Massachusetts, created by combining the Company's skin care treatment
center previously located in Framingham, Massachusetts with the spa in Boston.
A combined spa/skin care facility located in Scottsdale, Arizona was closed in
December 1997. The surgical skin care treatments performed in the LaserSpa(TM)
are administered by board-certified physicians under contract with CSCC. While
the target audience for the Company's core laser equipment tends to be medical
practice groups and other health care providers, its target audience for its
spa and skin care center is individuals who are typically reached through
entirely different marketing efforts. The cost structures, new client accretion
methods and other demands associated with the Company's new facilities are
largely untested, and the Company could continue to incur losses in connection
with its spa and skin care centers.
GOVERNMENTAL REGULATION. Medical devices are subject to approval before
they can be utilized for clinical studies or sold commercially. In addition,
the Company's activities in connection with its CSCC business may subject the
Company to additional regulation under state and federal laws. The process for
obtaining the necessary approvals and compliance with applicable regulations
can be costly and time consuming. Many foreign countries in which the Company
markets or may market its products have similar regulatory bodies and
restrictions. There is no assurance the Company will be able to obtain any
such government approvals or successfully comply with any such regulations in a
timely and cost-effective manner, if at all, and failure to do so may have an
adverse effect on the Company's financial condition and results of operations.
13
<PAGE>
CANDELA CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(CONTINUED)
RISKS ASSOCIATED WITH PRODUCT LIABILITY. The administration of medical and
cosmetic treatments using laser products is subject to various risks of
physical injury to the patient which may result in product liability or other
claims against the Company. The costs and resources involved in defending or
settling any such claims, or the payment of any award in connection therewith,
may adversely affect the Company's financial condition and operating results.
The Company maintains product liability insurance, but there is no assurance
that its policy will provide sufficient coverage for any claim or claims that
may arise, or that the Company will be able to maintain such insurance coverage
on favorable economic terms.
RAPID TECHNOLOGICAL CHANGE; COMPETITION. The medical laser industry is
subject to rapid and substantial technological development and product
innovations. The Company, to be successful, must be responsive to new
developments in laser technology and applications of existing technology, and
the Company's financial condition and operating results may be adversely
affected by the failure of new or existing products to compete favorably in
response to such technological developments. In addition, the Company competes
against numerous other companies offering products similar to the Company's
and/or alternative products and technologies, some of which have greater
financial, marketing and technical resources than the Company. There can be no
assurance the Company will be able to compete successfully. In addition, the
Company's CSCC operations face a host of competitors including hair salons,
health spas, massage therapists, aestheticians, health and fitness clubs,
personal trainers, dermatologists, plastic surgeons, cosmetic laser centers and
cosmetic retailers. The Company also believes its CSCC operations will face
competition from laser manufacturing companies that have, or may develop, plans
to open facilities based on concepts similar to the Candela LaserSpa(TM)
concept. Such competition could have a material adverse effect on the
Company's business, financial condition and results of operations. Further,
even if the Company is able to successfully compete, there can be no assurance
that it would be able to do so in a profitable manner.
RELIANCE ON ATTRACTING AND RETAINING KEY EMPLOYEES. The Company's success
will depend in large part on its ability to attract and retain highly-qualified
scientific, technical, managerial, sales and marketing, management and other
personnel. Competition for such personnel is intense and any decline in the
Company's ability to attract and retain such personnel may have adverse effects
on its financial condition and operating results.
14
<PAGE>
CANDELA CORPORATION
PART II OTHER INFORMATION
Item 6 Exhibits and Reports on Form 8-K
(a) Exhibits
Exhibit 27.1, Financial Data Schedule, page 14.
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the quarter ended
December 27, 1997.
15
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CANDELA CORPORATION
Registrant
Date: February 9, 1998 /s/ Gerard E. Puorro
---------------- ------------------------------------
Gerard E. Puorro
(President , Chief Executive Officer)
Date: February 9, 1998 /s/ F. Paul Broyer
---------------- ------------------------------------
F. Paul Broyer
(Vice President, Treasurer and
Chief Financial Officer)
16
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM SEC FORM 10-Q AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C> <C> <C> <C>
<PERIOD-TYPE> 3-MOS 3-MOS 6-MOS 6-MOS
<FISCAL-YEAR-END> JUN-27-1998 JUN-28-1997 JUN-27-1998 JUN-28-1997
<PERIOD-END> DEC-27-1997 DEC-28-1996 DEC-27-1997 DEC-28-1996
<CASH> 1,727 3,148 1,727 3,148
<SECURITIES> 0 0 0 0
<RECEIVABLES> 6,140 8,318 6,140 8,318
<ALLOWANCES> 912 187 912 187
<INVENTORY> 7,550 5,177 7,550 5,177
<CURRENT-ASSETS> 16,336 18,003 16,336 18,003
<PP&E> 8,056 5,782 8,056 5,782
<DEPRECIATION> 4,676 3,916 4,676 3,916
<TOTAL-ASSETS> 20,579 21,065 20,579 21,065
<CURRENT-LIABILITIES> 14,657 9,521 14,657 9,521
<BONDS> 0 0 0 0
0 0 0 0
0 0 0 0
<COMMON> 54 53 54 53
<OTHER-SE> 4,641 11,090 4,641 11,090
<TOTAL-LIABILITY-AND-EQUITY> 20,579 21,065 20,579 21,065
<SALES> 8,522 9,406 16,345 17,045
<TOTAL-REVENUES> 8,531 9,422 16,362 17,076
<CGS> 4,824 4,470 9,326 8,635
<TOTAL-COSTS> 4,824 4,750 9,326 8,635
<OTHER-EXPENSES> 8,079 3,606 12,154 6,631
<LOSS-PROVISION> 0 0 0 0
<INTEREST-EXPENSE> 69 15 96 31
<INCOME-PRETAX> (4,441) 1,051 (5,214) 1,779
<INCOME-TAX> 0 315 78 534
<INCOME-CONTINUING> (4,441) 736 (5,292) 1,245
<DISCONTINUED> 0 0 0 0
<EXTRAORDINARY> 0 0 0 0
<CHANGES> 0 0 0 0
<NET-INCOME> (4,441) 736 (5,292) 1,245
<EPS-PRIMARY> (0.82) 0.14 (0.97) 0.23
<EPS-DILUTED> (0.78) 0.13 (0.94) 0.22
</TABLE>
